September 25, 2015
Article
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
September 24, 2015
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.
Phase 3 Trial of Fablyn Plus Verzinio for Metastatic Breast Cancer Initiates Registration
‘I Was Winning and the Cancer Wasn’t’
Too Young for Cancer
Finding Gratitude in My Myeloma Experience